Huszno Joanna, Nowara Elżbieta
Clinical and Experimental Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
Contemp Oncol (Pozn). 2016;20(1):1-7. doi: 10.5114/wo.2016.58495. Epub 2016 Mar 16.
The HER2/neu (ERBB2) oncogene is amplified and/or overexpressed in approximately 20% of breast cancers, and is a strong prognostic factor for relapse and poor overall survival, particularly in node-positive patients. It is also an important predictor for response to trastuzumab, which has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. Treatment with the anti-HER2 humanized monoclonal antibody - trastuzumab significantly improves progression-free and overall survival among patients with HER2-positive breast cancer. However, in most patients with HER2-positive metastatic breast cancer, the disease progresses occurred, what cause the need for new targeted therapies for advanced disease. In clinical trials, there are tested new drugs to improve the results of treatment for this group of patients. This paper presents new drugs introduced into clinical practice for treatment of advanced breast cancer, whose molecular target are receptors of the HER2 family. In addition, new therapeutic strategies and drugs that are currently in clinical researches are discussed.
HER2/neu（ERBB2）癌基因在约20%的乳腺癌中发生扩增和/或过表达，是复发和总体生存率差的强有力预后因素，尤其是在淋巴结阳性患者中。它也是对曲妥珠单抗反应的重要预测指标，曲妥珠单抗已证实对HER2癌基因过表达或扩增的乳腺癌有效。使用抗HER2人源化单克隆抗体——曲妥珠单抗治疗可显著改善HER2阳性乳腺癌患者的无进展生存期和总体生存期。然而，在大多数HER2阳性转移性乳腺癌患者中，疾病仍会进展，这就需要针对晚期疾病的新靶向治疗。在临床试验中，正在测试新药以改善这组患者的治疗效果。本文介绍了已引入临床实践用于治疗晚期乳腺癌的新药，其分子靶点是HER2家族受体。此外，还讨论了目前正在进行临床研究的新治疗策略和药物。
